Clincosm LogoSign in Get a demo

Prognostic Nomogram of Extranodal NK/T-cell Lymphoma

Sponsor
Sun Yat-sen University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04554511
Collaborator
(none)
1,000
Enrollment
1
Location
4.1
Anticipated Duration (Months)
241.6
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study aims to evaluate prognostic factors for overall survival and explore risk progression-free survival in ENKTL, and establish a prognostic predictive nomogram for ENKTL patients.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    This is a retrospective cohort study using anonymized information from patients with ENKTL. The following criteria are required: (1) Patients diagnosed with ENKTL between January 1, 2000 and August 31, 2020; (2) Patients older than 18 years. The pathology of initial diagnosis was reviewed by designated pathologists.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    1000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Prognostic Nomogram of Extranodal NK/T-cell Lymphoma: A Multi-center Retrospective Study
    Actual Study Start Date :
    Aug 28, 2020
    Anticipated Primary Completion Date :
    Jan 1, 2021
    Anticipated Study Completion Date :
    Jan 1, 2021

    Arms and Interventions

    Arm Intervention/Treatment
    Training cohort

    Patients diagnosed with ENKTL, between January 1, 2000 and August 31, 2020.
    Validation Cohort

    Patients diagnosed with ENKTL, between January 1, 2000 and August 31, 2020.

    Outcome Measures

    Primary Outcome Measures

    1. Overall survival [5 year]

      Time between the date of diagnosis and any kinds of death

    Secondary Outcome Measures

    1. Progression-free survival [5 year]

      Time between the date of diagnosis and any kinds of death or relapse/progression

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Patients newly diagnosed with ENKTL

    • Patients diagnosed between January 1, 2000 and August 31, 2020

    • Patients older than 18 years

    Exclusion Criteria:
    • Patients who did not have complete clinical information or immunohistochemistry, or who were lost follow-up immediately after treatment.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Sun Yat-sen University Cancer Center Guangzhou Guangdong China 510060

    Sponsors and Collaborators

    • Sun Yat-sen University

    Investigators

    • Principal Investigator: Hua Wang, Sun Yat-sen University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    wanghua, associate chief physician, Sun Yat-sen University
    ClinicalTrials.gov Identifier:
    NCT04554511
    Other Study ID Numbers:
    • ENKTL-2020
    First Posted:
    Sep 18, 2020
    Last Update Posted:
    Sep 18, 2020
    Last Verified:
    Sep 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Lymphoma
    Lymphoma, T-Cell
    Lymphoma, T-Cell, Peripheral
    Lymphoma, Extranodal NK-T-Cell

    Study Results

    No Results Posted as of Sep 18, 2020